OS Therapies Says FDA's Shelving Of Commissioner's National Priority Voucher Has No Impact On Its Rare Pediatric Disease PRV Prospects

• OST-HER2 remains eligible for Priority Review Voucher ("PRV") if approved by the U.S. Food and Drug Administration's ("FDA") on or before September 30, 2029
• Company continues to benefit from its UK research and development program, through which it received approximately $900,000 in non-dilutive tax credits

Grasonville, Maryland--(Newsfile Corp. - November 13, 2026) - OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that the FDA's shelving of the Commissioner's National Priority Voucher ("CNPV") has no impact on the Company's rare pediatric disease PRV prospects. The shelving does not affect the FDA's rare pediatric disease PRV program, a statutory program currently authorized through September 30, 2029, under which vouchers are transferable. OST-HER2 may qualify for a PRV if it is approved by the FDA on or before September 30, 2029.